个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Shi, Yuankai[1,*1] * ; Chen, Gongyan[2] ; Wang, Xiang[3] ; Liu, Yunpeng[4] ; Wu, Lin[5] ; Hao, Yanrong[6] ; Liu, Chunling[7] ; Zhu, Shuyang[8] ; Zhang, Xiaodong[9] ; Li, Yuping[10] ; Liu, Jiwei[11] ; Cao, Lejie[12] ; Cheng, Ying[13] ; Zhao, Hui[14] ; Zhang, Shucai[15] ; Zang, Aimin[16] ; Cui, Jiuwei[17] ; Feng, Jian[18] ; Yang, Nong[19] ; Liu, Fei[20] ; Jiang, Yong[20] ; Gu, Chuan[20] ;
机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Med Oncol,Beijing Key, Beijing, Peoples R China [2]Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China [3]Xuzhou Cent Hosp, Dept Med Oncol, Xuzhou, Peoples R China [4]First Hosp China Med Univ, Dept Med Oncol, Shenyang, Peoples R China [5]Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Thorac Med Dept 2,Affiliated Canc Hosp, Changsha, Peoples R China [6]Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Med Oncol, Nanning, Peoples R China [7]Xinjiang Med Univ, Dept Pulm Med, Canc Hosp, Urumqi, Peoples R China [8]Xuzhou Med Coll, Dept Resp Med, Affiliated Hosp, Xuzhou, Peoples R China [9]Nantong Canc Hosp, Dept Med Oncol, Nantong, Peoples R China [10]Wenzhou Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp 1, Wenzhou, Peoples R China [11]Dalian Med Univ, Dept Oncol, Affiliated Hosp 1, Dalian, Peoples R China [12]USTC, Dept Resp Med, Affiliated Hosp 1, Hefei, Peoples R China [13]Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China [14]Second Hosp Anhui Univ, Dept Resp & Crit Care Med, Hefei, Peoples R China [15]Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Oncol Inst, Dept Oncol, Beijing, Peoples R China [16]Hebei Univ,Dept Med Oncol,Affiliated Hosp,Baoding,Peoples R China [17]First Hosp Jilin Univ, Canc Ctr, Changchun, Peoples R China [18]Nantong Univ, Dept Resp Med, Affiliated Hosp, Nantong, Peoples R China [19]Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Dept Med Oncol,Affiliated Canc Hosp,Lung Canc & Ga, Changsha, Peoples R China [20]Shanghai Allist Pharmaceut, Shanghai, Peoples R China
出处：
DOI： 10.1016/j.jtho.2022.07.1143
ISSN：

关键词： NSCLC EGFR Furmonertinib AST2818 CNS

摘要：
Introduction: Furmonertinib (AST2818) is a pan-EGFR tyrosine kinase inhibitor with central nervous system (CNS) antitumor activity. We report the CNS efficacy of furmo-nertinib compared with gefitinib in untreated EGFR-sensi-tizing mutation-positive NSCLC from the FURLONG study.Methods: FURLONG was a randomized, double-blind, phase 3 study conducted in 55 hospitals in the People's Republic of China. Patients 1:1 randomly received furmonertinib 80 mg once daily or gefitinib 250 mg once daily treatment. At screening, all the patients underwent brain imaging exam-ination. Patients with asymptomatic steady CNS metastases at baseline constituted this preplanned CNS subgroup analysis.Results: A total of 358 patients were enrolled in the FURLONG study. In the 133 (37%) patients who had measurable or nonmeasurable CNS lesions, CNS progression-free survival was 20.8 months (95% confi-dence interval [CI]: 15.2-25.3) in the furmonertinib group and 9.8 months (95% CI: 7.2-18.0) in the gefitinib group (hazard ratio = 0.40 [95% CI: 0.23-0.71], p = 0.0011). In the 60 patients (17%) who had measurable CNS lesions, CNS objective response rate was 91% (95% CI: 72-99) with furmonertinib and 65% (95% CI: 48-80) with gefitinib (OR = 6.82 [95% CI: 1.23-37.67], p = 0.0277). The least -square mean of CNS depth of response was 62% (95% CI: 51-72) in the furmonertinib group and 39% (95% CI: 30- 47) in the gefitinib group, the mean difference was 23% (95% CI: 10-37, p = 0.0011). Conclusions: Furmonertinib first-line treatment was found to have superior efficacy in CNS progression-free survival, CNS objective response rate, and CNS depth of response compared with gefitinib in patients with EGFR-mutated NSCLC with CNS metastases.(c) 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

基金：
Shanghai Allist Pharmaceuticals; China National Major Project for New Drug Innovation [2017ZX09304015]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2022]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Med Oncol,Beijing Key, Beijing, Peoples R China [*1]Department of MedicalOncology, National Cancer Center/National Clinical Research Center forCancer/Cancer Hospital, Chinese Academy of Medical Sciences & PekingUnion Medical College, Beijing Key Laboratory of Clinical Study onAnticancer Molecular Targeted Drugs, Beijing 100021, People’s Republic of China
通讯作者：
通讯机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Med Oncol,Beijing Key, Beijing, Peoples R China [*1]Department of MedicalOncology, National Cancer Center/National Clinical Research Center forCancer/Cancer Hospital, Chinese Academy of Medical Sciences & PekingUnion Medical College, Beijing Key Laboratory of Clinical Study onAnticancer Molecular Targeted Drugs, Beijing 100021, People’s Republic of China
推荐引用方式(GB/T 7714)：
Shi Yuankai,Chen Gongyan,Wang Xiang,et al.Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study[J].JOURNAL OF THORACIC ONCOLOGY.2022,17(11):1297-1305.doi:10.1016/j.jtho.2022.07.1143.
APA：
Shi, Yuankai,Chen, Gongyan,Wang, Xiang,Liu, Yunpeng,Wu, Lin...&Gu, Chuan.(2022).Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.JOURNAL OF THORACIC ONCOLOGY,17,(11)
MLA：
Shi, Yuankai,et al."Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study".JOURNAL OF THORACIC ONCOLOGY 17..11(2022):1297-1305

相关文献

[1]A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions [2]克唑替尼对alk阳性nsclc患者cns的影响 [3]Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus ge fi tinib as fi rst-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer [4]A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs [5]Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study [6]Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation [7]Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study [8]Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study. [9]Furmonertinib versus gefitinib in treatment-naive EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG) [10]Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis

资源点击量：15100 今日访问量：0 总访问量：960 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持：重庆聚合科技有限公司 地址：保定市莲池区裕华东路212号